Matrix-Bound Vesicles Carrying IL-33 for Fibrosis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic modalities are inadequate for preventing or reversing fibrosis caused by cardiac injury, such as myocardial infarction or ischemia, and immune-mediated attacks after solid organ transplants, leading to chronic allograft rejection and heart failure.
Innovation Solution
Administration of matrix-bound nanovesicles (MBVs) derived from extracellular matrix, containing interleukin-33 (IL-33) and lysyl oxidase, which activate a pro-remodeling M2 macrophage phenotype through a non-canonical ST2-independent pathway, reducing pro-inflammatory myeloid cell infiltration and promoting tissue repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic modalities are used to treat fibrosis and chronic rejection, then current treatment options are available, but they are inadequate for preventing or reversing fibrosis and leading to poor outcomes
Solution Approach 1:
The patent changes the therapeutic parameter by using matrix-bound nanovesicles (MBVs) containing IL-33 instead of conventional therapies. The MBVs are characterized by specific parameters: they bind to the extracellular matrix, have a size of 50-500 nm, and contain specific cargo (IL-33, miRNAs, proteins). This parameter change enables the therapy to effectively shift macrophage phenotypes and inhibit fibrosis, achieving superior clinical outcomes compared to conventional modalities.
Solution Approach 2:
The invention uses composite material principles by creating nanovesicles that combine multiple functional components: a lipid bilayer membrane structure, bound extracellular matrix proteins (such as fibronectin, collagen), and encapsulated bioactive cargo (IL-33, microRNAs, proteins). This composite structure enables simultaneous functions of tissue binding, immune modulation, and delivery of therapeutic cargo, resolving the inadequacy of single-component conventional therapies.
2Reliability
If matrix-bound nanovesicles containing IL-33 are administered to treat fibrosis and chronic rejection, then pro-inflammatory myeloid cell infiltration is reduced and tissue repair is promoted, but the mechanism involves a non-canonical ST2-independent pathway that is less understood
Solution Approach 1:
The patent identifies matrix-bound nanovesicles as intermediary carriers that deliver IL-33 and other bioactive molecules to target cells. The MBVs serve as the intermediary between the therapeutic agent and the cell surface, facilitating the non-canonical ST2-independent signaling pathway. This intermediary approach simplifies the overall mechanism by using the nanovesicle as a delivery vehicle that bypasses the need for direct ST2 receptor engagement, while still achieving effective macrophage phenotype switching and inhibition of fibrosis.
Data Source
AI summary
Methods are disclosed for treating a subject with a disorder, such as, but not limited to, a) fibrosis of an organ or tissue; b) solid organ transplant rejection; or c) a cardiac disease that is not myocardial infarction or myocardial ischemia. These methods include selecting a subject having or at risk of having the disorder, and administering to the subject a therapeutically effective amount of isolated nanovesicles derived from an extracellular matrix, wherein the nanovesicles contain interleukin (IL)-33 and comprise lysyl oxidase, and wherein the nanovesicles a) do not express CD63 or CD81, or b) are CD63loCD81lo. In additional embodiments, methods are disclosed for increasing myoblast differentiation.